|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4409450A
(en)
|
1982-07-29 |
1983-10-11 |
Amp Incorporated |
Double pole membrane switch having preferred sequence closing feature
|
|
ZA842025B
(en)
|
1983-03-21 |
1984-11-28 |
Hoffmann La Roche |
Interleuken-2
|
|
FR2573436B1
(fr)
|
1984-11-20 |
1989-02-17 |
Pasteur Institut |
Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
|
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
WO1991018088A1
(en)
|
1990-05-23 |
1991-11-28 |
The United States Of America, Represented By The Secretary, United States Department Of Commerce |
Adeno-associated virus (aav)-based eucaryotic vectors
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
CA2130578A1
(en)
|
1992-04-17 |
1993-10-28 |
Geewananda P. Gunawardana |
Taxol derivatives
|
|
EP1024198A3
(en)
|
1992-12-03 |
2002-05-29 |
Genzyme Corporation |
Pseudo-adenoviral vectors for the gene therapy of haemophiliae
|
|
US5776468A
(en)
|
1993-03-23 |
1998-07-07 |
Smithkline Beecham Biologicals (S.A.) |
Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
|
|
FR2705361B1
(fr)
|
1993-05-18 |
1995-08-04 |
Centre Nat Rech Scient |
Vecteurs viraux et utilisation en thérapie génique.
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
SK282843B6
(sk)
|
1993-07-13 |
2002-12-03 |
Rhone-Poulenc Rorer S. A. |
Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
EP1167379A3
(en)
|
1994-07-15 |
2004-09-08 |
University Of Iowa Research Foundation |
Immunomodulatory oligonucleotides
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
|
UA68327C2
(en)
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
US5912264A
(en)
|
1997-03-03 |
1999-06-15 |
Bristol-Myers Squibb Company |
6-halo-or nitrate-substituted paclitaxels
|
|
JP4139860B2
(ja)
|
1997-11-10 |
2008-08-27 |
ストラカン インターナショナル リミティッド |
浸透増強および刺激減少システム
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
AT406376B
(de)
|
1998-01-16 |
2000-04-25 |
Immuno Ag |
Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
|
|
JPH11268865A
(ja)
|
1998-03-20 |
1999-10-05 |
Omron Corp |
用紙仕分け装置及び方法
|
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
|
US6198323B1
(en)
|
1999-01-28 |
2001-03-06 |
Lucent Technologies Inc. |
Flip-flop having gated inverter feedback structure with embedded preset/clear logic
|
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
|
GB9927444D0
(en)
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
|
US20030180352A1
(en)
|
1999-11-23 |
2003-09-25 |
Patel Mahesh V. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
US6967023B1
(en)
|
2000-01-10 |
2005-11-22 |
Foamix, Ltd. |
Pharmaceutical and cosmetic carrier or composition for topical application
|
|
CO5280224A1
(es)
|
2000-02-02 |
2003-05-30 |
Univ Florida State Res Found |
Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
|
|
DK1263936T3
(da)
|
2000-03-14 |
2006-02-13 |
Bavarian Nordic As |
andret stamme af den modificerede Vacciniavirus Ankara (MVA)
|
|
EP1272630A2
(en)
|
2000-03-16 |
2003-01-08 |
Genetica, Inc. |
Methods and compositions for rna interference
|
|
ES2254408T4
(es)
|
2000-04-25 |
2007-10-01 |
Immunex Corporation |
Procedimiento de tratamiento de tumores usando terapia fotodinamica.
|
|
US7179483B2
(en)
|
2000-04-26 |
2007-02-20 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
|
US20060057553A1
(en)
|
2000-05-30 |
2006-03-16 |
Estuardo Aguilar-Cordova |
Chimeric viral vectors for gene therapy
|
|
US8512718B2
(en)
|
2000-07-03 |
2013-08-20 |
Foamix Ltd. |
Pharmaceutical composition for topical application
|
|
JP4845327B2
(ja)
|
2000-07-21 |
2011-12-28 |
千葉県 |
腫瘍特異的プロモーター
|
|
AU2002211490A1
(en)
|
2000-10-04 |
2002-04-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of using capsid protein from flaviviruses and pestiviruses
|
|
EP1213025A1
(de)
|
2000-12-06 |
2002-06-12 |
Laboratoires Serobiologiques(Societe Anonyme) |
Kosmetische und/oder dermopharmazeutische Zubereitungen enthaltend Extrakte aus den Blättern der Pflanze Argania spinosa
|
|
EP1341817A2
(en)
|
2000-12-08 |
2003-09-10 |
Novo Nordisk A/S |
Tff peptides
|
|
ATE437221T1
(de)
|
2001-05-14 |
2009-08-15 |
Gbp Ip Llc |
Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
|
|
JP2003009883A
(ja)
|
2001-07-05 |
2003-01-14 |
Mitsubishi Pharma Corp |
マスト細胞の細胞死誘発剤
|
|
WO2003035683A2
(en)
|
2001-10-26 |
2003-05-01 |
Uffe Holmskov |
Surfactant protein-d and atherosclerosis
|
|
US7368122B1
(en)
|
2002-03-08 |
2008-05-06 |
Dow Pharmaceutical Sciences |
Skin cream
|
|
KR20120002613A
(ko)
|
2002-08-12 |
2012-01-06 |
제네렉스, 인코포레이티드 |
폭스바이러스 및 암과 관련된 방법 및 조성물
|
|
EP2186811A1
(en)
|
2002-08-23 |
2010-05-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
GB0226251D0
(en)
|
2002-11-11 |
2002-12-18 |
San Raffaele Centro Fond |
Acetylated protein
|
|
US20040143026A1
(en)
|
2002-12-31 |
2004-07-22 |
Shah Kishore R. |
Bioadhesive hydrophilic composition for treatment of mammalian skin
|
|
NZ570709A
(en)
|
2003-06-13 |
2010-04-30 |
Univ Pennsylvania |
Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
|
|
ATE420160T1
(de)
|
2003-06-18 |
2009-01-15 |
Genelux Corp |
Modifizierte rekombinante vacciniaviren, verwendungen davon
|
|
AU2004272607B2
(en)
|
2003-09-11 |
2008-11-06 |
Cornerstone Therapeutics Inc. |
Monoclonal antibodies against HMGB1
|
|
EP1528101A1
(en)
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
|
WO2005054451A1
(ja)
|
2003-12-05 |
2005-06-16 |
Hokkaido Technology Licensing Office Co., Ltd. |
高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
|
|
DE102004030044A1
(de)
|
2004-06-22 |
2006-01-12 |
Birken Gmbh |
Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
|
|
US8007806B2
(en)
|
2005-01-20 |
2011-08-30 |
Isconova Ab |
Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
|
|
US20100094560A1
(en)
|
2006-08-15 |
2010-04-15 |
Prometheus Laboratories Inc. |
Methods for diagnosing irritable bowel syndrome
|
|
DK2062023T4
(en)
|
2006-08-25 |
2017-02-20 |
The Government Of The Us Secretary Dept Of Health And Human Services |
INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS
|
|
WO2008023077A2
(en)
*
|
2006-08-25 |
2008-02-28 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin |
Compositions and methods for modulating an immune response
|
|
EP2097517B1
(en)
|
2006-10-16 |
2014-06-04 |
Genelux Corporation |
Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
|
|
GB0702695D0
(en)
|
2007-02-12 |
2007-03-21 |
Ark Therapeutics Ltd |
Production of vectors
|
|
US8003363B2
(en)
|
2007-05-14 |
2011-08-23 |
Bavarian Nordic A/S |
Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
|
|
ES2560871T3
(es)
|
2007-07-10 |
2016-02-23 |
Apogenix Gmbh |
Proteínas de fusión de colectina de la superfamilia de TNF
|
|
WO2009054996A2
(en)
|
2007-10-25 |
2009-04-30 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
SI4269578T1
(sl)
|
2008-03-06 |
2024-07-31 |
Halozyme, Inc. |
Sestava topne hialuronidaze
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
ES2532896T5
(es)
|
2008-05-14 |
2018-03-20 |
Immatics Biotechnologies Gmbh |
Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
|
|
EP2349296B1
(en)
|
2008-08-21 |
2017-04-05 |
Ottawa Hospital Research Institute |
Engineered synergistic oncolytic viral symbiosis
|
|
CN101381742A
(zh)
|
2008-10-23 |
2009-03-11 |
浙江理工大学 |
晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
|
|
EP2184297A1
(en)
|
2008-11-07 |
2010-05-12 |
Hla-G Technologies |
HLA-G polypeptides and pharmaceutical uses thereof
|
|
ES2385251B1
(es)
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
CA2709292A1
(en)
|
2009-07-10 |
2011-01-10 |
The Governors Of The University Of Alberta |
Oncolytic viruses and methods for treating neoplastic disorders
|
|
JP5686814B2
(ja)
|
2010-09-17 |
2015-03-18 |
独立行政法人科学技術振興機構 |
Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
AU2012204467B2
(en)
|
2011-01-04 |
2016-08-18 |
Sillajen, Inc. |
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
|
|
EP2527459A1
(en)
|
2011-05-02 |
2012-11-28 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Blood-based gene detection of non-small cell lung cancer
|
|
EP2739293B1
(en)
|
2011-08-05 |
2020-06-10 |
SillaJen Biotherapeutics, Inc. |
Methods and compositions for production of vaccina virus
|
|
FI20115914L
(fi)
|
2011-09-16 |
2013-03-17 |
Oncos Therapeutics Ltd |
Muunnettu onkolyyttinen virus
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10806697B2
(en)
|
2012-12-21 |
2020-10-20 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
|
EP3473708B1
(en)
|
2012-07-24 |
2021-01-27 |
The General Hospital Corporation |
Oncolytic virus therapy for resistant tumors
|
|
WO2014048500A1
(en)
|
2012-09-28 |
2014-04-03 |
Probiogen Ag |
Novel mva virus and uses thereof
|
|
US9180091B2
(en)
|
2012-12-21 |
2015-11-10 |
Therapeuticsmd, Inc. |
Soluble estradiol capsule for vaginal insertion
|
|
KR20140122603A
(ko)
|
2013-04-10 |
2014-10-20 |
신라젠(주) |
세포외 피막성 백시니아 바이러스의 생성과 관련된 단백질을 코딩하는 폴리뉴클레오티드로 형질전환된 숙주세포
|
|
DK2986311T3
(en)
|
2013-04-18 |
2019-02-25 |
Tilt Biotherapeutics Oy |
IMPROVED ADOPTIVE CELL THERAPY
|
|
KR102322510B1
(ko)
|
2013-07-18 |
2021-11-08 |
브이아이비 브이지더블유 |
수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
|
|
RS65104B1
(sr)
|
2013-08-22 |
2024-02-29 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Onkolitičke imunoterapije
|
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
KR102442436B1
(ko)
*
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
MA39818A
(fr)
|
2014-03-30 |
2017-02-08 |
Benevir Biopharm Inc |
Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
|
|
US20160060311A1
(en)
|
2014-08-27 |
2016-03-03 |
Daewoong Jo |
Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Lung Cancer Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Lung Cancer Compositions Comprising the Same
|
|
PT3186281T
(pt)
|
2014-08-28 |
2019-07-10 |
Halozyme Inc |
Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
|
|
BR112017007765B1
(pt)
*
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
|
CN105829930B
(zh)
|
2014-10-24 |
2019-04-26 |
华为技术有限公司 |
模式复用解复用器和交换节点
|
|
CN115300622A
(zh)
|
2015-02-25 |
2022-11-08 |
纪念斯隆-凯特琳癌症中心 |
使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
|
|
EP3217993A1
(en)
|
2015-07-20 |
2017-09-20 |
Virttu Biologics Limited |
Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
|
|
WO2017043815A1
(en)
|
2015-09-08 |
2017-03-16 |
Sillajen, Inc. |
Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof
|
|
EP4643874A3
(en)
|
2015-12-22 |
2026-02-11 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
KR20180133395A
(ko)
|
2016-02-25 |
2018-12-14 |
메모리얼 슬로안 케터링 캔서 센터 |
암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
AU2017332367B2
(en)
|
2016-09-21 |
2021-12-23 |
Stephen H. Thorne |
High mobility group box i mutant
|
|
WO2018058258A1
(en)
|
2016-09-30 |
2018-04-05 |
University Health Network |
Recombinant oncolytic viruses for cancer therapy
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
US11185586B2
(en)
|
2016-11-22 |
2021-11-30 |
Alloplex Biotherapeutics, Inc. |
Allogeneic tumor cell vaccine
|
|
KR20190112263A
(ko)
|
2016-12-12 |
2019-10-04 |
멀티비르 인코포레이티드 |
암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
|
|
AU2018223211B2
(en)
|
2017-02-21 |
2025-02-27 |
Adelaide university |
T cells expressing chemokine receptors for treating cancer
|
|
TWI672677B
(zh)
|
2017-03-31 |
2019-09-21 |
鈺立微電子股份有限公司 |
用以融合多深度圖的深度圖產生裝置
|
|
WO2019055860A1
(en)
|
2017-09-15 |
2019-03-21 |
The Texas A&M University System |
METHODS FOR IMPROVING IMMUNOTHERAPY IN THE TREATMENT OF CANCER
|
|
EP3703723A4
(en)
|
2017-10-31 |
2021-12-15 |
KaliVir Immunotherapeutics, Inc. |
ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
|
|
WO2019148109A1
(en)
|
2018-01-26 |
2019-08-01 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
|
|
EP3788142A4
(en)
|
2018-05-02 |
2022-04-27 |
Tonix Pharma Holdings Limited |
SYNTHETIC CHIMERIC VACCINE VIRUS
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
CA3116192C
(en)
|
2018-11-06 |
2025-09-23 |
Calidi Biotherapeutics (Nevada), Inc. |
IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
|
|
TW202038994A
(zh)
|
2019-01-14 |
2020-11-01 |
美商醫格耐免疫治療公司 |
重組痘瘡病毒及其使用方法
|
|
WO2020165730A1
(en)
|
2019-02-14 |
2020-08-20 |
Ignite Immunotherapy, Inc. |
Recombinant vaccinia virus and methods of use thereof
|
|
US20230405105A1
(en)
|
2019-09-20 |
2023-12-21 |
Transgene Sa |
Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody
|
|
WO2021116943A1
(en)
|
2019-12-12 |
2021-06-17 |
Ignite Immunotherapy, Inc. |
Variant oncolytic vaccinia virus and methods of use thereof
|
|
WO2021140435A1
(en)
|
2020-01-09 |
2021-07-15 |
Pfizer Inc. |
Recombinant vaccinia virus
|
|
AU2021310520A1
(en)
|
2020-07-14 |
2023-02-16 |
Pfizer Inc. |
Recombinant vaccinia virus
|
|
CN112668865A
(zh)
|
2020-12-23 |
2021-04-16 |
贵阳市城市轨道交通集团有限公司 |
一种城市地铁风险动态分析方法
|